D-0147-2020 Class II Terminated
FDA drug recall D-0147-2020 was initiated by Nephron Pharmaceuticals Corporation Dba Nephron Sterile Compounding Center on Oct 9, 2019 and is designated Class II. Reason for recall: GMP Deviations: potential glass contamination The recall status is terminated (terminated Dec 1, 2020). Affected quantity: 1855 bags.
Recall details
- Product Type
- Drugs
- Report Date
- Oct 30, 2019
- Initiation Date
- Oct 9, 2019
- Termination Date
- Dec 1, 2020
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 1855 bags
Product description
PF-Fentanyl Citrate (2 mcg/mL)* & Bupivacaine HCl 0.0625 in 0.9% Sodium Chloride Injection-250 mL Total Dose: (500 mcg/156.3 mg)/250 mL, Rx Only, Nephron 503B Outsourcing Facility 4500 12th St. Extension West Columbia, SC 29172 NDC 69374-0525-25
Reason for recall
GMP Deviations: potential glass contamination
Distribution pattern
Nationwide.
Code information
Lots: FB9001 A Exp. 10/31/2019, FB9001B Exp. 10/31/2019; FB9013A Exp. 12/08/2019; FB9015A Exp. 12/14/2019
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0147-2020
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026